RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Tarsus Pharmaceuticals Stock

Tarsus Pharmaceuticals Equity 2025

Tarsus Pharmaceuticals Equity

224.53 M USD

Ticker

TARS

ISIN

US87650L1035

In 2025, Tarsus Pharmaceuticals's equity was 224.53 M USD, a 13.98% increase from the 196.99 M USD equity in the previous year.

Tarsus Pharmaceuticals Aktienanalyse

What does Tarsus Pharmaceuticals do?

Tarsus Pharmaceuticals Inc is an emerging pharmaceutical company specializing in the development of novel therapies for eye diseases. The company was founded in 2016 and is headquartered in Irvine, California. Tarsus focuses on identifying groundbreaking innovative technologies and drugs for the treatment of eye diseases. Tarsus's business model is based on the idea that there are still no effective treatment methods for many eye diseases. For this reason, the company invests in research and development to close this gap and give affected patients new hope. Tarsus's goal is to improve eye health through the development of drugs and therapies. Tarsus is divided into several divisions that focus on different areas of ophthalmology. These include the development of drugs for the treatment of dry eyes, eyelid twitching, age-related macular degeneration, and other eye diseases. Tarsus's first product, TP-03, is a medication for the treatment of conjunctivitis caused by the bacterium Demodex. This condition affects millions of people worldwide and is often difficult to treat. TP-03 is a novel medication specifically targeting Demodex, thus providing an effective treatment option. Another product from Tarsus is TP-04, a medication for the treatment of dry eyes. This condition is one of the most common eye diseases worldwide, affecting millions of people. TP-04 aims to combat the causes of dry eyes and alleviate the symptoms. Tarsus also has a promising pipeline of products in various stages of development. These include medications for age-related macular degeneration, eyelid twitching, and other eye diseases. Tarsus has entered into partnerships with major pharmaceutical companies and research institutions. These partnerships allow the company to bring its products to market faster and reach a larger audience. Overall, Tarsus has the potential to revolutionize ophthalmology and improve the treatment of many eye diseases. The company has a dedicated team of researchers and scientists who are committed to advancing the development of new therapies and medications. Tarsus Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Tarsus Pharmaceuticals's Equity

Tarsus Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Tarsus Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Tarsus Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Tarsus Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Tarsus Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Tarsus Pharmaceuticals stock

What is the equity of Tarsus Pharmaceuticals this year?

Tarsus Pharmaceuticals has equity of 224.53 M USD this year.

What was the equity of Tarsus Pharmaceuticals compared to the previous year?

The equity of Tarsus Pharmaceuticals has increased/decreased by 13.98% increased compared to the previous year.

What impact does a high equity have on investors of Tarsus Pharmaceuticals?

A high equity is advantageous for investors of Tarsus Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Tarsus Pharmaceuticals?

A low equity can be a risk for investors of Tarsus Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Tarsus Pharmaceuticals affect the company?

An increase in equity of Tarsus Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Tarsus Pharmaceuticals affect the company?

A reduction in equity of Tarsus Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Tarsus Pharmaceuticals?

Some factors that can affect the equity of Tarsus Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Tarsus Pharmaceuticals so important for investors?

The equity of Tarsus Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Tarsus Pharmaceuticals take to change the equity?

To change equity, Tarsus Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Tarsus Pharmaceuticals pay?

Over the past 12 months, Tarsus Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Tarsus Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Tarsus Pharmaceuticals?

The current dividend yield of Tarsus Pharmaceuticals is .

When does Tarsus Pharmaceuticals pay dividends?

Tarsus Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Tarsus Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Tarsus Pharmaceuticals located?

Tarsus Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Tarsus Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Tarsus Pharmaceuticals from 8/12/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/12/2025.

When did Tarsus Pharmaceuticals pay the last dividend?

The last dividend was paid out on 8/12/2025.

What was the dividend of Tarsus Pharmaceuticals in the year 2024?

In the year 2024, Tarsus Pharmaceuticals distributed 0 USD as dividends.

In which currency does Tarsus Pharmaceuticals pay out the dividend?

The dividends of Tarsus Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Tarsus Pharmaceuticals

Our stock analysis for Tarsus Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Tarsus Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.